October 12-14, 2017

ECNM Meeting

On behalf of the Organizing Committee, it is a great pleasure to invite you to attend the ECNM MEETING which will be held in Paris, France on October 12-14, 2017.

The CEREMAST (French Reference Center For Mastocytosis) is hosting the annual meeting of the European Competence Network for Mastocytosis (ECNM) on October 12-14, 2017 and we hereby warmly invite you to join this meeting. The ECNM (www.ecnm.net) was founded in 2002 as a network of European Centers with special experience in mastocytosis. The aims of the network are to promote clinical excellence, education and scientific research into the disease. The network facilitates co-operation between specialties and specialists, clinical medicine and basic science. Annual meetings are aimed at clinicians, scientists and allied health professionals with a common interest in mastocytosis held bringing together experts in the field for discussions, presentation of scientific results and education.  The CEREMAST is a multidisciplinary centre for Mastocytosis, located at Necker Hospital, active from 2006, and a Centre of Excellence in the ECNM. We look forward to welcoming you at the annual ECNM meeting in Paris!

Yours sincerely, on behalf of the CEREMAST,

Michel Arock, Olivier Hermine, Olivier Lortholary and Christine Bodemer French Reference Center For Mastocytosis (CEREMAST) Necker Hospital and Imagine Institute, Paris (France)

0
participants
0
speakers
0
conferences

Multidisciplinary outpatients group

ANDRZEJEWSKI Barbara
Secretary – IMAGINE – Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutical implications – PARIS
AGOPIAN Julie
Laboratory engineer – AFIRMM – CEREMAST – Paoli Calmettes Institute – Marseille
AROCK Michel
PharmD PhD – Hematologist – CEREMAST – Chairman of the ECNM – Pitié-Salpêtrière Hospital – PARIS
BARETE Stéphane
MD, PhD – Dermastologist – CEREMAST – Pitié-Salpetrière Hospital – PARIS
BELLAIS Anne-Florence
OFFICE MANAGER – CEREMAST – IMAGINE – Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutical implications – PARIS
BODEMER Christine
MD, PhD – Dermastologist & Pediatrist – CEREMAST – Necker Hospital – PARIS
BOUKTIT Hassiba
ARC – CEREMAST – Necker Hospital – PARIS
CANIONI Danielle
MD – Hematopathologist – CEREMAST – Necker Hospital – PARIS
DAMAJ Gandhi
MD, PhD – Hematologist – CEREMAST – Unisversity Hospital – CAEN
DEWACHTER Pascale
MD – PhD – Anesthesiologist – Consultant in allergo-anesthesia – CEREMAST – GH – Paris Seine Saint Denis
DUBREUIL Patrice
PhD – Laoratory Molecular Biologist INSERM – CEREMAST – CRCM – MARSEILLE
FRAITAG Sylvie
PhD – Pathologist & Dermatologist – CEREMAST – Necker Hospital – PARIS
FRENZEL Laurent
MD, PhD – Rheumatologist – Hematologist – Necker hospital – Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutical implications – PARIS
GEORGIN LAVIALLE Sophie
MD – PhD – Internist – CEREMAST – Tenon Hospital – PARIS
GRAPIN Camille
Psychologist – CEREMAST – Necker Hospital – PARIS
GUILLEM Flavia
PhD – Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutical implications – PARIS
HANSSENS Katia
Technician of molecular biology – AFIRMM – CEREMAST – Paoli Calmettes Institute – Marseille
HERMINE Olivier
MD, PhD – Hématologist – CEREMAST – Necker hospital – Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutical implications – PARIS
LHERMITTE Ludovic
MD, PhD Hematology – CEREMAST – Necker Hospital – PARIS
LORTHOLARY Olivier
MD, PhD – Infectiologist – CEREMAST – Necker hospital – PARIS
MAOUCHE CHRETIEN Leila
PhD – Hematology – stem cells – Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutical implications – PARIS
POLIVKA Laura
MD, PhD – Dermatologist – CEREMAST – Necker hospital – Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutical implications – PARIS

Endorsements

Scientific info

Topics

  • Basic Science and Mast Cell Research
  • Diagnosis and management of Mastocytosis
  • Multidisciplinary approach to Mastocytosis
  • Mast Cell Activation Syndromes in adults and in children
  • New Diagnostic and Prognostic Parameters of Mastocytosis
  • Treatment of mastocytosis with antimediator and with cytoreductive drugs (results of ongoing trial and new proposal)
  • Pathology and Molecular Markers in Systemic Mastocytosis

Committees

  • Michel Arock
  • Olivier Hermine
  • Olivier Lortholary
  • Christine Bodemer
  • Gandhi Damaj
  • Stéphane Barete
  • Anne-Florence Bellais
Karin Hartmann MD, Professor of Dermatology – Head, Allergy Section Department of Dermatology – University Hospital Schleswig-Holstein, Campus Luebeck – Ratzeburger Allee 160 23538 Luebeck Germany
Peter Valent MD – Hematology – Department of Hematology, Internal Medicine I, Medical University of Vienna Professor, Scientific Director of the Ludwig Boltzmann Cluster Oncology and Head of a Research group at the Department of Internal Medicine I at the Medical University of Vienna, Austria Coordinator of the ECNM
Hans-Peter Horny MD, Professor of Pathology, Institute of Pathology Munich, Germany Deputy coordinator of the ECNM
Wolfgang R. Sperr MD – Medical University of Vienna – Ludwig Boltzmann Cluster Oncology Department of Internal Medicine I – Division of Hematology & Hemostaseology – Währinger Gürtel 18-20 – 1090 Vienna, Austria
Michel Arock PHD-HEMATOLOGIST, PharmD, CEREMAST Pitié-Salpêtrière Hospital Laboratory of Molecular and Cellular Oncology CNRS UMR 8113 Chairman of the ECNM PARIS
Cem Akin MD, PhD, Professor, Specialties: Internal Medicine, Allergy And Immunology University of Michigan, Department of Allergy – Northville Health Center – 39901 Traditions Dr Ste 210 – Northville – MI 48168
Stephen J Galli M.D. , Chair, Department of Pathology, Professor of Pathology and of Microbiology and Immunology, Mary Hewett Loveless, M.D. Professor, Co-Director, Center for Genomics and Personalized Medicine, Stanford University School of Medicine
Jason R. Gotlib MD, MS, Professor of Medicine Stanford, CA, Dr. Gotlib is Professor of Medicine (Hematology) at the Stanford University School of Medicine/Stanford Cancer Institute.
Dean D. Metcalfe MD – internal medicine, Chief, Laboratory of Allergic Diseases, Chief, Mast Cell Biology Section National Institute of Allergy and Infectious Diseases – Building 10, Room 11C207 – 10 Center Drive – Bethesda, MD 20892
Lawrence B. Schwartz MD, PhD Charles & Evelyn Thomas Professor of Medicine, Chair, Division of Rheumatology, Allergy & Immunology Associate Chair for Research, Professor of medicine, Division of General Internal Medicine BOX 980263 – McGuire Hall – Richmond, Virginia 23219

Keynote speakers

  • BRETTERKLIEBER AGNES
  • FUCHS DAVID
  • HADZIJUSUFOVIC EMIR
  • SCHNEEWEIß MATHIAS
  • SPERR WOLFGANG R.
  • VALENT PETER
  • SABATO VITO
  • VANDENBERGHE PETER
  • DOUBEK MICHAEL
  • BROESBY-OLSEN SIGURD
  • AROCK MICHEL
  • BARETE STEPHANE
  • GUILLEM FLAVIA
  • HERMINE OLIVIER
  • LORTHOLARY OLIVIER
  • POLIVKA LAURA
  • AL-ALI HAIFA KATHRIN
  • BROCKOW KNUT
  • CHRISTEN DEBORAH
  • HORNY HANS-PETER
  • HARTMANN KARIN
  • ILLERHAUS ANJA
  • JÄKEL NADJA
  • JAWHAR MOHAMAD
  • PANSE JENS
  • REITER ANDREAS
  • SCHWAAB JULIANA
  • SHOUMARIYEH KHALID
  • SOTLAR KARL
  • VON BUBNOFF NIKOLAS
  • BONADONNA PATRIZIA
  • BONIFACIO MASSIMILIANO
  • ELENA CHIARA
  • MALCOVATI LUCA
  • MERANTE SERENA
  • TRIGGIANI MASSIMO
  • ZANOTTI ROBERTA
  • GORSKA ALEKSANDRA
  • LANGE MAGDALENA
  • NIEDOSZYTKO MAREK
  • NEDOSZYTKO BOGUSLAW
  • ALVAREZ-TWOSE IVAN
  • ESCRIBANO LUIS
  • ORFAO ALBERTO
  • GUNNAR NILSSON
  • KLUIN-NELEMANS HANNEKE
  • OUDE ELBERINK HANNEKE
  • YAVUZ AKIM SELIM
  • AKIN CEM
  • CARTER MELODY
  • CASTELLS MARIANA
  • GEORGE TRACY
  • GOTLIB JASON
  • METCALFE DEAN D.
  • SCHWARTZ LAWRENCE B.

Preliminary program

Afternoon and evening Company-Driven Advisory Boards
Morning Company-Driven Advisory Boards 13:30 Welcome Coffee 14:00 Welcome Notes • Michel Arock & Olivier Hermine (Paris, France) 14:10 ECNM Homepage • Emir Hadzijusufovic (Vienna, Austria) 14:20 Status of the ECNM in 2017 and Plan until 2020 • Peter Valent (Vienna, Austria) & Michel Arock (Paris, France) 14:30 Presentation of the Researcher of the Year 2017 • Michel Arock (Paris, France) & Peter Valent (Vienna, Austria) 14:40 Development of interventional anti-neoplastic drug therapies in advanced mastocytosis • Hanneke Kluin-Nelemans (Groningen, The Netherlands) 15:10 Coffee Break 15:30 Session I: Diagnostic Evaluation and Prognostication in SM-AHN • Chair: Peter Valent & Michel Arock 15:30 Diagnostic immunophenotyping in SM-AHN: markers and standards • Luis Escribano & Alberto Orfao (Salamanca, Spain) 15:50 Histologic and immunohistochemical standards in SM-AHN • Hans-Peter Horny (Munich, Germany) 16:10 Diagnostic molecular profiling and prognostication in SM-AHN • Andreas Reiter (Mannheim, Germany) 16:30 Coffee Break 16:50 Session II: Clinical Management and Therapeutic Approaches • Chairs: Olivier Hermine & Luis Escribano 16:50 Efficacy of masitinib in patients with severely symptomatic ISM Olivier Lortholary & Olivier Hermine (Paris, France) 17:10 Response and resistance to midostaurin in advanced SM: impact of molecular markers • Mohamad Jawhar (Mannheim, Germany) 17:30 Indications for imatinib in patients with mastocytosis • Ivan Alvarez-Twose (Toledo, Spain) 17:50 Clinical research activity in advanced SM at Stanford • Jason Gotlib (Stanford, CA, USA) 18:10 Preclinical studies with Blueprint compounds in mastocytosis • Michel Arock (Paris, France) 18:30 Preclinical studies with the Deciphera compound DCC-2618 • Mathias Schneeweiß (Vienna, Austria) 18:50 Expression of CD30 in different categories of mastocytosis: implication for prognosis and targeted therapy • Stéphane Barete (Paris, France)
8:00 Welcome Coffee 8:30 Overview of ECNM Registry Projects, Perspectives, and Publication Policies  Peter Valent (Vienna, Austria) 8:45 The ECNM Registry Projects: Technical and Contract Issues  Wolfgang R. Sperr (Vienna, Austria) 9:00 Session IIIA: Presentation of First Wave Projects of the ECNM Registry • Chairs: Michel Arock & Massimo Triggiani 9:00 Age-adjusted diagnosis and prognostication in mastocytosis (PR1) • Anja Illerhaus & Karin Hartmann (Cologne/Lübeck, Germany) 9:15 Impact of allergic disorders and anaphylaxis in mastocytosis (PR2) • Boguslaw Nedoszytko (Gdansk, Poland) 9:30 Impact of bone marrow mastocytosis (BMM) (PR3) • Roberta Zanotti, Massimiliano Bonifacio & Patrizia Bonadonna (Verona, Italy) 9:45 Clinical impact of serum tryptase levels in the FU in SM (PR4) • Nadja Jäkel & Haifa Kathrin Al-Ali (Leipzig, Germany) 10:00 Clinical significance of blood count abnormalities in mastocytosis (PR5) • Anja Illerhaus & Hanneke Kluin-Nelemans (Cologne, Germany & Groningen, The Netherlands) 10:15 Impact of serum chemistry on diagnosis and treatment of SM (PR6) • Juliana Schwaab & Andreas Reiter (Mannheim, Germany) 10:30 Coffee Break 11:00 Spectrum of mediator-related symptoms in mastocytosis (PR7) • Massimo Triggiani (Salerno, Italy) 11:15 Treatment of patients with mastocytosis: outcomes & response rates (PR8) • Luca Malcovati, Chiara Elena & Serena Merante (Pavia, Italy) 11:30 Skin lesions in different categories of mastocytosis (PR9) • Agnes Bretterklieber (Graz, Austria) 11:45  Proposed IPPS for patients with mastocytosis (PR10) • Wolfgang R. Sperr (Vienna, Austria) 12:00  Risk of SM in patients with MIS (PR11) • David Fuchs (Linz, Austria) 12:15  Lunch Break 13:20 Session IIIB: Presentation of Second Wave Projects of the ECNM Registry • Chairs: Wolfgang R. Sperr & Hanneke Kluin-Nelemans 13:40 Characterization and prognosis of patients with smouldering SM (SSM) (PR12) • Anja Illerhaus & Karin Hartmann (Cologne/Lübeck, Germany) 14:00 Clinical impact of organomegaly in patients with systemic mastocytosis (PR13) • Mohamad Jawhar & Andreas Reiter (Mannheim, Germany) 14:20 Impact of the body mass index in patients with mastocytosis (PR14) • Aleksandra Gorska & Marek Niedoszytko (Gdansk, Poland) 14:40 Clinical features and course of patients with various forms of ASM (PR15) • Khalid Shoumariyeh & Nikolas von Bubnoff (Freiburg, Germany) 15:00 Coffee Break 15:20 Clinical course of patients with diverse variants of MCL (PR16) • Jason Gotlib (Stanford, USA) 15:40 Features, course, and prognosis of typical ISM (excluding BMM/SSM) (PR17) • Michael Doubek (Brno, Czech Republic) 16:00 General Discussion 16:20 Session IIIC: Presentation of Potential New ECNM Registry Projects (3rd Wave) • Chairs: Peter Valent & Karin Hartmann 16:20 Pure cutaneous mastocytosis in adults: clinical features and course (PR18) • Knut Brockow (Munich, Germany) 16:40 AHN: frequency, distribution, sub-types, and prognostic impact (PR19) • Olivier Hermine (Paris, France) 17:00 Bone lesions and related symptoms in mastocytosis (PR20) • Akim Selim Yavuz (Istanbul, Turkey) 17:20 Prognostic impact of percent mast cells in BM smears vs BM histologies (PR21) • Vito Sabato (Antwerpen, Belgium) 17:40 Diagnostic and prognostic impact of cytogenetics in SM (PR22) • Peter Vandenberghe (Leuven, Belgium) 18:00 Prognostic impact of platelet counts in SM and comparison to hemoglobin and ANC counts (PR23) • Deborah Christen & Jens Panse (Aachen, Germany) 18:20 Closed registry steering committee session: discussion, nomination, selection, and approval of new ECNM registry projects
8:00 Welcome Coffee 8:30  Session IV: Basic Science, Pathology, and Molecular Markers • Chair: Alberto Orfao & Cem Akin 8:30 Updated WHO classification of mast cell disorders Karl Sotlar (Munich, Germany) 8:50 Clinicopathologic features of mast cell leukemia Tracy George (Albuquerque, NM, USA) 9:10 Tryptase as diagnostic parameter in daily practice Lawrence B. Schwartz (Richmond, VA, USA) 9:30 Mast cell growth and activation: from understanding mechanisms to therapy Dean D. Metcalfe (Bethesda, MD, USA) 9:50 Coffee Break 10:10 Session V: Anaphylaxis and mastocytosis • Chair: Dean D. Metcalfe & Knut Brockow 10:30 Allergy and mastocytosis: risk evaluation and management Hanneke Oude Elberink (Groningen, The Netherlands) 10:50 News in Hymenoptera venom allergy and mastocytosis Patrizia Bonadonna (Verona, Italy) 11:10 Diagnosis and management of MCAS: update 2017 Cem Akin (Ann Arbor, MI, USA) 11:30 Coffee Break 12:00 Session VI: Hot Topics and Late Breaking Abstracts • Chair: Olivier Lortholary & Lawrence B. Schwartz 12:00 MCL and SM-AML: experiences from a single institution • Mohamad Jawhar & Andreas Reiter (Mannheim, Germany) 12:15 Diagnostic algorithm in suspected mastocytosis: the Nordic experience Sigurd Broesby-Olsen (Odense, Denmark) 12:30 Single cell analysis of KIT D816V mutation during hematopoiesis Gunnar Nilsson (Stockholm, Sweden) 12:45 Effects of XPO1 antagonists on KIT D816V+ neoplastic MCs Flavia Guillem (Paris, France) 13:00 Genetic insights into the familial forms of mastocytosis Laura Polivka (Paris, France) 13:15 Ultra rush desensitization for hymenoptera anaphylaxis in Mastocytosis: the Next Generation Mariana Castells (Boston, MA, USA) 13:30 Pediatric mastocytosis: diagnosis & management Melody Carter (Bethesda, MD, USA) 13:45 Improvement of cutaneous mastocytosis: place for topical and systemic treatments Stéphane Barete (Paris, France) 14:00 Summary and Concluding Remarks • Olivier Hermine, Peter Valent & Michel Arock
[pdf-embedder url= »https://ecnm-2017.emeetingpack.com//wp-content/uploads/sites/7/2017/05/ECNM-Paris-2017-Preliminary-Program.pdf » width= »100% »] Download PDF (2 mo)

General info

Contacts  /  Venue

Contacts

Local Organizing Committee: Michel Arock, Olivier Hermine Tel: +33 1 42 17 73 50, +33 6 11 55 45 91, +33 1 42 75 43 50 Email: Michel ArockOlivier Hermine
Mrs Anne-Florence Bellais

Venue

Institut Imagine 24, Boulevard de Montparnasse – 75015 PARIS – FRANCE +33 1 42 75 42 00 – +33 1 42 75 43 50

Itinerary

HOW IMAGINE INSTITUTE:

Map of the site and nearest metro stations: please follow this link.

Imagine is a research and innovative healthcare institute of a new type.

Imagine was created in 2007. The need to gather researchers, doctors and patients in one building quickly became apparent. The necessary funds had to be collected and then, with Assistance Publique-Hôpitaux de Paris, the construction of the new Institute began. On land made available by the AP-HP, the Institute is located on the corner of boulevard Montparnasse and rue du Cherche-Midi. With some 19,000 sq. m dedicated to genetic diseases, it pioneers a new consultation paradigm, adapted to the children’s disabilities and designed to provide support for their families. It brings together the players of research and treatment of genetic diseases in one place.

Set up around a vast atrium bathed in natural light, it consists of :

  • Research areas with laboratories and efficient technical facilities
  • Areas for clinical care intended for genetic consultations
  • A clinical investigation center
  • A biological resource center
  • Rare diseases reference centers

The project management has been entrusted to the Assistance Publique-Hôpitaux de Paris (AP – HP), in the context of a procurement contract for the design-realization. It has been allocated to Urbaine de Travaux, Valéro Gadan Architects, Ateliers Jean Nouvel and INGEROP. They designed a pioneer architectural concept based on an innovative organization promoting synergy between the different teams, the keystone of the Imagine Institute’s organization.

Favoring glass and natural materials and fitting perfectly into the urban landscape, the Imagine Institute also features several gardens. The façades are adorned with etched glass reminiscent of a DNA sequence, symbolically illustrating the raison d’être of this Institute of Genetic Diseases.

« The corner of boulevard Montparnasse and rue du Cherche-Midi could not be more Parisian. We would like it to be hospitable in both senses of the word. Of course the Imagine building has to be functional but not in the restrictive sense of functionalism. The pleasure of working there is indeed a measure of how effective the research is. The image of the Imagine Institute therefore has to be welcoming, open and bright. Light, highly accurate architecture symbolizes the forefront of research today. »

Within the architecture a real surprise is revealed, a hidden dimension. Overall the heart of the building is naturally lit: overhead views of the sky and two openings at the side overlooking the garden to the Northwest. Due to the interior balconies of the labs, researchers see the consultation area for children and its internal garden.

The official language of the Meeting is English.
All visitors entering France must have a valid passport or an identity card for European citizens. Citizens of some countries will be required an entrance visa. If you need an official letter for your visa, please contact the Organizing Comittee.
  • shops are open from 9 am through 7/8 pm Monday to Saturday; many shops located in the historical city centre are open on Sunday
  • some supermarkets are also open on Sunday morning
  • banks’ usual opening hours are from 9 am to 4 pm Monday to Friday
  • there will not be banking facilities provided in the Symposium Centre; the nearest ATM is 100m from the Symposium site
Neither the Local Organizing Committee nor the Symposium Centre will assume responsibility for injury or damage to persons or property during the Meeting.

Registration online

0/200 participants

Registration

Participation

About you

Your institution

* required
Envoi

Once pre registered you will receive an automatic email.

After that the Organizing Secretariat will send you a confirmation email.

The registration includes:

  • conference materials
  • access to all sessions during the conference
  • coffee breaks and lunches as indicated in the programme

The registration is open for a maximum of 150 participant.

The event is not CME accredited.

Accommodation

HOTEL BOOKING SERVICE

Click here to find a vast selection of accommodation and to make your reservation. Please book as soon as possible to take advantage of cheaper rates.

Hôtel Novotel Paris Centre Gare Montparnasse   17 Rue du Cotentin, 75015 Paris   +33 (0)1 53 91 23 75 From 158€ /night Best Western Sèvres Montparnasse   153 Rue de Vaugirard, 75015 Paris   +33 (0)1 47 34 56 75 From 169€ /night Hôtel La Parizienne   33 Boulevard du Montparnasse, 75006 Paris   +33 (0) 1 45 48 75 64 From 189€ /night
Timhotel Paris Gare Montparnasse   22 Rue de l’Arrivée, 75015 Paris   +33 (0) 1 45 48 96 62 From 115€ / night Miramar   6 Place Bienvenüe, 75015 Paris   +33 (0)1 45 48 62 94 From 115€ /night Hôtel Mayet   3 Rue Mayet, 75006 Paris   +33(0) 1 47 83 21 35 From 129€ /night Hôtel ibis Paris Gare Montparnasse 15ème   71 boulevard de Vaugirard, 75015 Paris   +33 (0)1 43 20 89 12 From 130€ /night BEST WESTERN Hotel Le Montparnasse   37 Boulevard du Montparnasse, 75006 Paris   +33 (0)1 45 44 85 37 From 135€ /night Edouard 6 Montparnasse   61 Boulevard du Montparnasse, 75006 Paris   +33 (0)1 45 48 94 99 From 145€ /night Hôtel ibis Paris Tour Montparnasse 15ème   22 Avenue du Maine, 75015 Paris   +33 (0) 1 45 48 95 52 From 165€ /night Odéon Hôtel   3 rue de l’Odéon, 75006 Paris   +33 (0) 1 43 25 90 67 From 194€ /night

Paris pocket guide

[pdf-embedder url= »https://ecnm-2017.emeetingpack.com//wp-content/uploads/sites/7/2017/Paris-City-Guide-2016-2017.pdf »] Download PDF (280 ko)